Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008
Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007
Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007
Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI) Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Systemic bioavailability (BA) and pharmacodynamics (PD) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) or a novel breath-triggered inhaler (BTI) Source: International Congress 2017 – Inhalers and their use Year: 2017
Formoterol via turbuhaler (F) versus salbutamol via pressurized metered-dose inhaler (SB) in acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Comparison of the effects of beclomethasone HFA (BDP- HFA) pMDI with beclomethasone CFC (BDP-CFC) pMDI on 10-hour urinary cortisol in healthy subjects Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Safety of beclomethasone HFA (HFA BDP) pMDI compared with beclomethasone CFC pMDI (CFC BDP) over 12 weeks Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001
Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005